Results 271 to 280 of about 130,782 (308)
Some of the next articles are maybe not open access.
Prospects for MEK inhibitors for treating cancer
Expert Opinion on Drug Safety, 2014The MAPK pathway is a signaling network that plays a key role in many normal cellular processes and in a large number of human malignancies. One of its effectors, MEK, is essential for the carcinogenesis of different tumors. In recent years, several drugs able to inhibit MEK have been assessed in clinical trials.
Juan, Martin-Liberal +2 more
openaire +2 more sources
MEK inhibitors: a patent review 2008 – 2010
Expert Opinion on Therapeutic Patents, 2011MAPK/extracellular signal-regulated kinase (MEK) inhibitors target the Ras/Raf/MEK/ERK signaling pathway, which is important in cell growth, differentiation and development. The pathway has been implicated in the progression of a variety of diseases, in particular cancer, as well as in immune and inflammatory diseases such as rheumatoid arthritis ...
openaire +2 more sources
2007
Signal transduction is a complex process that involves a network of molecules that facilitate communication within, between, and among cells and their environment. Molecules involved in signal transduction include receptor tyrosine kinases (RTKs), non-receptor tysrosine kinases (NTRKs), serine-threonine kinases (STKs), and G proteins.
openaire +1 more source
Signal transduction is a complex process that involves a network of molecules that facilitate communication within, between, and among cells and their environment. Molecules involved in signal transduction include receptor tyrosine kinases (RTKs), non-receptor tysrosine kinases (NTRKs), serine-threonine kinases (STKs), and G proteins.
openaire +1 more source
MEK inhibitor: the MM magic bullet?
Blood, 2007MEK/ERK pathway activation in multiple myeloma (MM) is critical for cell growth and survival. Tai and colleagues have demonstrated that the MEK1/2 inhibitor AZD6244 targets both MM cells and osteoclasts. The RAS/RAF/MEK/ERK pathway is activated in many types of cancer through various mechanisms,
openaire +1 more source
Melanom: Lebensqualität besser mit MEK-Inhibitor
Im Focus Onkologie, 2014In der METRIC-Studie war das Gesamtuberleben von Melanompatienten mit BRAF-V600-Mutation unter MEK-Inhibitor Trametinib im Vergleich zu einer Chemotherapie signifikant verlangert. Und die Lebensqualitat?
openaire +1 more source
Trends in kinase drug discovery: targets, indications and inhibitor design
Nature Reviews Drug Discovery, 2021Misty M Attwood, Stefan Knapp
exaly
Highly Selective MEK Inhibitors
Current Enzyme Inhibition, 2010Chih-Shia Lee, Nicholas S. Duesbery
openaire +1 more source